AstraZeneca chalks up another phase III fail as COPD drug misses target

Chief medical officer Dr Sean Bohen called the result disappointing

words clinical pinned to a clipboard
Fasenra failed to show a statistically significant impact on people suffering exacerbations of moderate to very severe chronic obstructive pulmonary disease

AstraZeneca PLC's (LON:AZN) rather patchy success rate for late-stage clinical trials continued after its drug Fasenra failed to show a statistically significant impact on people suffering exacerbations of moderate to very severe chronic obstructive pulmonary disease (COPD).

The top-line results from the TERRANOVA phase III study followed the announcement earlier this month that another final-phase assessment of the treatment, called, GALATHEA, had drawn a blank.

READ: AstraZeneca receives more solid data for its Imfinzi lung cancer treatment

Chief medical officer Dr Sean Bohen said: "These results are disappointing because uncontrolled COPD patients already on dual or triple inhaled therapy need new treatment options. 

"We will now analyse the complete data sets from the GALATHEA and TERRANOVA trials to further understand these results."


Quick facts: AstraZeneca

Price: 7258 GBX

Market: LSE
Market Cap: £95.22 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Impax Asset Management reveals key themes investors should...

Impax Asset Management Group PLC (LON:IPX) Head of Client Services and Business Development David Richardson tells Proactive key themes investors should look out for in 2020.  Richardson says he's seeing expansion in developing renewable energy projects in Europe, increased interested in...

16 hours, 55 minutes ago

2 min read